Reduction in severity and extent of myocardial infarction when nitroglycerin and methoxamine are administered during coronary occlusion.
D000818:Animals; D003327:Coronary Disease / Q000188:drug therapy*; D003331:Coronary Vessels / Q000187:drug effects; D003402:Creatine Kinase / Q000378:metabolism; D004285:Dogs; D004567:Electrodes, Implanted; D007275:Injections, Intravenous; D008729:Methoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality; D009206:Myocardium / Q000201:enzymology; D005996:Nitroglycerin / Q000008:administration & dosage / Q000627:therapeutic use*
D003402:Creatine Kinase; D005996:Nitroglycerin; D008729:Methoxamine